Monday, July 28, 2008 2:56:23 PM
Hi Nano,
I believe "the street" wants to see interest from a Pharma co. Any Pharma. Japan would be great on EKC. That would certainly give investors that concrete proof that the claimed test results have been verified and accepted with 10's of Millions of $'s in an "up-front" type deal.
That will give a whole new meaning to this company rather than "Here's a great new guy who joined with us".
We will need something soon that has that type of "meat" or IMO we're going back under a buck.
Also IMO, these latest PR's are not helping SP. They are fine and are positive news but let's face it investors have been waiting and needing a bit more for quite a while now.
You asked so that's the way I see it.
Personally I would feel a lot better at $3.00 right now since I'm deep under water at this point and hoping like the rest of us for something "significant"....and soon!
Tough day right now at $1.06 a share.
I believe "the street" wants to see interest from a Pharma co. Any Pharma. Japan would be great on EKC. That would certainly give investors that concrete proof that the claimed test results have been verified and accepted with 10's of Millions of $'s in an "up-front" type deal.
That will give a whole new meaning to this company rather than "Here's a great new guy who joined with us".
We will need something soon that has that type of "meat" or IMO we're going back under a buck.
Also IMO, these latest PR's are not helping SP. They are fine and are positive news but let's face it investors have been waiting and needing a bit more for quite a while now.
You asked so that's the way I see it.
Personally I would feel a lot better at $3.00 right now since I'm deep under water at this point and hoping like the rest of us for something "significant"....and soon!
Tough day right now at $1.06 a share.
Recent NNVC News
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
